BIO-key International, Inc. (BKYI) Q2 2024 Earnings Call Transcript Summary
BIO-key International, Inc. (BKYI) Q2 2024 Earnings Call Transcript Summary
The following is a summary of the BIO-key International, Inc. (BKYI) Q2 2024 Earnings Call Transcript:
以下是BIO-key International, Inc. (BKYI) Q2 2024 業績會議通話內容摘要：
Financial Performance:
金融業績：
Q2 2024 revenues decreased to $1.1 million from $1.9 million in Q2 2023, negatively impacted by delayed software license contracts and lower services revenue.
Gross profit margin improved to 77% in Q2 2024, up from 69% in Q2 2023, primarily due to higher services gross margin.
Net loss decreased to $1.7 million in Q2 2024, improved from $2.6 million in Q2 2023.
Q2 2024 營業收入從Q2 2023的190萬美元下降至110萬美元，受延遲的軟件許可合同和較低的服務收入的負面影響。
Q2 2024 毛利潤率提高到77％，高於Q2 2023的69％，主要由於更高的服務毛利率。
Q2 2024 淨虧損爲170萬美元，改善自Q2 2023的260萬美元。
Business Progress:
業務進展：
Expansion of PortalGuard deployments in healthcare and public sector clients including the University of Iowa Hospital and Dayton Children's Hospital.
Introduction of the Passkey:YOU product for phoneless, tokenless authentication, targeting unserved workplace scenarios.
Launched solutions on the Amazon Web Services marketplace, aiming to facilitate global accessibility and increase market penetration.
在醫療保健和公共部門客戶（包括愛荷華大學醫院和戴頓兒童醫院）中擴大了PortalGuard的部署。
推出Passkey:YOU產品，針對未得到滿足的工作場所場景，實現無需手機、無需令牌進行身份驗證。
在亞馬遜網絡服務市場推出解決方案，旨在促進全球可訪問性和增加市場滲透率。
Opportunities:
機會：
The growth in enterprise demand for secure Zero Trust deviceless IAM solutions, driven by cybersecurity regulations and insurance requirements.
Strategic value from technologies and products enhancing the company's market position notably in regulated environments like healthcare, banking, defense, and government.
企業對網絡安全法規和保險要求推動了安全零信任無設備IAM解決方案的需求增長。
技術和產品的戰略價值提高了公司在受監管環境（如醫療保健、銀行、國防和政府）中的市場地位。
Risks:
風險：
Revenues significantly lower than expected due to delays in closing large contracts and implementing strategic projects, particularly in the EMEA region and within new large-scale partnerships.
營業收入大幅低於預期，原因是推遲關閉大型合同和實施戰略項目，尤其是在EMEA地區和新的大型合作伙伴關係中。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。